RecruitingNot ApplicableNCT07254988
Gut Peptides and Bone Remodeling in Children With Neuromuscular Disorders
Sponsor
University of Copenhagen
Enrollment
8 participants
Start Date
Mar 24, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
Both GIP and GLP-2 reduce bone resorption (measured as CTX) in healthy adult individuals. In this study, we will investigate whether GIP and GLP-2 reduce CTX in children with spinal muscular atrophy, duchenne muscular dystrophy, or cerebral palsy.
Eligibility
Min Age: 10 YearsMax Age: 17 Years
Inclusion Criteria1
- \- Diagnosis with Cerebral palsy (CP), Duchenne muscular dystrophy (DMD) or Spinal muscular atrophy (SMA) resulting in the need of a wheelchair
Exclusion Criteria5
- Use of anti-resorptive medication
- Confounding illnesses
- Pregnancy
- Allergy towards the components given on the test days
- Hgb<6.5 mmol/L
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERMeal test
Ingestion of an oral liquid meal (nutridrink), 3.3 mL/kg body weight.
OTHERGIP + GLP-2
Subcutaneous GIP + GLP-2 injection (1 mL containing 100 microgram GIP + 1 mL containing 400 microgram GLP-2).
OTHERPlacebo
Subcutaneous saline injection (2 mL isotonic saline).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07254988
Related Trials
Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy
NCT071729711 location
Dorsal Root Electrical Stimulation in Children With Cerebral Palsy
NCT077150061 location
Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials
NCT076747589 locations
Clinical Improvement Due to the Home Use of Agilik in Children With Cerebral Palsy
NCT066226556 locations
Local Vibration for Drooling in Children With Cerebral Palsy
NCT076264241 location